Novel advances in targeted drug delivery

Area of Science:

• Drug discovery and development
• Nanotechnology in medicine
• Pharmaceutical sciences

Background:

• Developing novel drug molecules is costly, time-consuming, and often unsuccessful.
• Repurposing existing drugs by enhancing their properties offers a more efficient clinical approach.
• Strategies like nanoparticle drug delivery systems are actively researched to improve drug performance.

Purpose of the Study:

• To investigate the effectiveness of various strategies for improving existing drugs.
• To analyze the application and administration routes of nanoparticle-based drug delivery systems.
• To understand the reasons behind the high failure rate of nanoparticle drug formulations in clinical trials.

Main Methods:

• Review of current drug development and repurposing strategies.
• Analysis of nanoparticle-based drug delivery systems, including administration routes.
• Examination of regulatory approval data from agencies like the FDA and EMA for nanoparticle formulations.
• Investigation into the failure points of nanoparticle drugs during pre-clinical and clinical trials.

Main Results:

• Nanoparticle drug delivery systems are a key strategy for enhancing drug bioavailability, targetability, efficacy, and safety.
• Approved nanoparticle formulations predominantly target cancer treatment.
• A significant number of nanoparticle drug formulations fail to pass pre-clinical or clinical trials.
• Understanding failure mechanisms is essential for improving the success rate of these advanced drug delivery systems.

Conclusions:

• Enhancing existing drugs, particularly through nanotechnology, presents a promising alternative to de novo drug development.
• Improving the understanding of nanoparticle drug formulation failures is critical for advancing their clinical translation.
• Further research into the reasons for trial attrition is necessary to increase the approval rate of nanoparticle-based therapeutics.